Priyavadan Shah
Cardiovascular Disease · Cary, NCNPI 1679561369
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 370 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,267 and has fallen 91.2% since, to $199 in 2023.
Across 370 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AstraZeneca$759
- Amgen$611
- E.r. Squibb & Sons, L.L.C.$514
- Novartis$479
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$399
- plus $2K from 23 others
Across 378 payments — averaging $2289.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$577K
- Esperion Therapeutics, Inc.$236K
- Novartis$53K
What the payments were for
- Food & beverage$5,677100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 97 | $1,073 |
| AstraZeneca | 35 | $759 |
| Amgen | 34 | $611 |
| E.r. Squibb & Sons, L.L.C. | 51 | $514 |
| Novartis | 33 | $479 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $399 |
| Esperion Therapeutics, Inc. | 11 | $240 |
| Medtronic(2 entities) | 5 | $173 |
| Edwards Lifesciences | 5 | $163 |
| Sanofi-aventis U.S. LLC | 10 | $157 |
| Amarin Pharma, Inc. | 8 | $151 |
| Novo Nordisk | 9 | $140 |
| Boehringer Ingelheim | 6 | $139 |
| Abbott | 5 | $108 |
| Lilly USA, LLC | 2 | $76 |
| Merck | 6 | $75 |
| Actelion Pharmaceuticals US, Inc. | 7 | $75 |
| Chiesi USA, Inc. | 4 | $62 |
| Pfizer | 4 | $60 |
| Janssen Scientific Affairs, LLC | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Abiomed | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $23 |
| Cardiovascular Systems Inc. | 2 | $18 |
| Lundbeck LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,677 in reported general payments places this provider in the 70th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Other cardiovascular disease in Cary
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.